; and (ii) the number of such applications that are for a drug on the drug shortage list under section 506E of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356e ). (c) Annual report on inspections Not later than March 1 of each year, the Secretary shall post on the Internet website of the Food and Drug Administration— (1) the average and median amount of time, following a request by staff of the Food and Drug Administration reviewing an application or report submitted under an applicable section described in subparagraph (A), (B), or (C), to schedule and complete inspections of facilities necessary for— (A) approval of a drug under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ); (B) approval of a device under section 515 of such Act ( 21 U.S.C. 360e ); and (C) clearance of a device under section 510(k) of such Act ( 21 U.S.C. 360(k) ); and (2) the average and median amount of time to schedule and complete for-cause inspections of facilities of drugs and devices. II Incentivizing competition 201. Expediting generic competition Chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 et seq.) is amended by inserting after section 506G the following: 506H. Expediting generic drug development (a) In general The Secretary shall, at the request of an applicant, expedite the development and review of an application under subsection (j) of section 505 for a drug— (1) for which there are not more than 3 approved drug products listed under section 505(j)(7)